Medical Board of California Opioid and Controlled Substance Prescribing Investigations: Red Flags for California Doctors

How the Medical Board of California Identifies Outlier Prescribers in 2026

The Medical Board of California approach to prescribing enforcement has shifted substantially over the past decade. Where once investigations arose almost entirely from patient complaints or adverse outcomes, today a significant share originate from data analytics applied to the California Controlled Substance Utilization Review and Evaluation System (CURES).

CURES is California’s Prescription Drug Monitoring Program operated by the California Department of Justice. It records every controlled substance prescription dispensed in California and generates analytical reports identifying outlier patterns.

The tactical framework for responding to any MBC investigation is covered in our guide on responding to a Medical Board of California complaint. The full disciplinary pathway is covered in our MBC disciplinary process guide. The sanction ladder that applies to prescribing cases is in our MBC sanctions explained guide.

The wider US context for state board prescribing enforcement is covered in our state board disciplinary process complete guide. California-specific features including CURES integration and DEA coordination make the local application distinct.

The Medical Board of California now receives and acts on several streams of prescribing intelligence. CURES analytics flag prescribers with unusual patterns. Pharmacy suspicious activity reports identify specific prescriptions that raised concerns at dispensing.

Coroner and medical examiner reports of overdose deaths often reference prescription records of involved prescribers. Hospital reports under Business and Professions Code Section 805 trigger review when prescribing was a factor in privilege action. DEA referrals share federal investigation information with the MBC. And patient and family complaints remain an important input.

The practical consequence for California physicians is that prescribing patterns are no longer invisible until a specific patient complains. An outlier prescribing pattern may be flagged by CURES analytics, reviewed by MBC staff, and referred for formal investigation without any single patient complaint ever being filed. Prevention requires the same standards as if a complaint were pending.

CURES Data and What Medical Board of California Investigators Look For

Understanding what CURES shows to investigators is the first step in evaluating your own prescribing risk profile. CURES is not a passive repository; it generates analytical reports and supports queries that identify specific prescribing patterns.

California Health and Safety Code Section 11165.1 requires most California prescribers to consult CURES before initially prescribing Schedule II-IV controlled substances and at regular intervals thereafter. Failure to document CURES consultation is itself a practice issue that MBC investigators note.

The specific data points investigators examine in CURES include the following.

• Total volume by drug class. Total quantity of Schedule II opioids, Schedule IV benzodiazepines, Schedule III testosterone, and other controlled substances prescribed over a defined period.
• Morphine milligram equivalents (MME) per day. Patient-level calculation of daily opioid dose. Prescribing above 90 MME/day draws particular attention based on CDC opioid prescribing guidelines.
• Concurrent benzodiazepine and opioid prescribing. Specific combination flagged by CDC and state guidelines. Patients receiving both concurrently are identified at the prescriber level.
• Duration of therapy. Chronic opioid therapy beyond 90 days with escalating dose is a pattern of concern.
• Patient count and concentration. Unusually high numbers of controlled substance patients or high concentration of patients receiving similar regimens.
• Geographic patterns. Patients travelling unusual distances to see the prescriber. Clusters of patients from specific zip codes.
• Prescribing to patients seeing multiple prescribers. Patients with controlled substance prescriptions from multiple prescribers simultaneously.
• Early refills. Patients receiving refills before the previous prescription should have been exhausted.
• Dose escalation velocity. Rapid dose increases over short time periods.
• CURES consultation compliance. Frequency with which the prescriber actually accessed CURES before writing prescriptions, as recorded in CURES access logs.

Prescribing Patterns That Commonly Trigger Investigations

Beyond the data patterns CURES surfaces, several specific prescribing behaviours are recurring triggers for Medical Board of California investigation. These are the patterns that appear repeatedly in published MBC Decisions involving prescribing.

The recurring triggers include the following.

1. High-dose chronic opioid therapy. Sustained prescribing above 90 MME/day for non-cancer pain without documented attempts at dose reduction or multimodal alternatives.
2. Concurrent opioid and benzodiazepine prescribing. Prescribing both drug classes to the same patient despite CDC and California-specific guidelines warning of increased overdose risk.
3. Prescribing without documented CURES review. Writing controlled substance prescriptions without the documented CURES consultation required by Health and Safety Code Section 11165.1.
4. Thin or absent documentation. Prescriptions written without documented history, examination, diagnosis, and treatment rationale sufficient to support the clinical necessity.
5. No controlled substance agreement. Chronic opioid therapy without a signed controlled substance agreement or informed consent specific to opioid therapy.
6. No urine drug screening. Chronic controlled substance prescribing without periodic urine drug screening to verify compliance and absence of diversion.
7. Prescribing to family members or staff. Particularly for controlled substances and particularly where prescriptions are repeated or scheduled.
8. Dose escalation without documented failure of current regimen. Increasing doses without documenting that the current regimen has failed to provide adequate relief or function.
9. Continuing the same regimen after adverse events. No change in prescribing after documented overdose, ER visit, or other adverse event related to prescribed medications.
10. Long-distance patients. Repeated patients who travel unusual distances to see the prescriber, particularly across state lines.

DEA Coordination: Parallel Federal and State Risk

Controlled substance prescribing investigations rarely occur in isolation at the state level. The Medical Board of California and the Drug Enforcement Administration maintain information sharing arrangements, and parallel proceedings are common.

The DEA proceedings operate on a separate administrative track from the MBC. A California physician under both proceedings may face two simultaneous investigations with overlapping but distinct evidentiary standards and procedural timelines.

The features of DEA involvement that California physicians should understand include the following.

• DEA Office of Diversion Control. The federal body responsible for investigating potential diversion, improper dispensing, and registration violations. Maintains its own investigators and its own administrative law framework.
• DEA Order to Show Cause. The federal equivalent of an Accusation, charging violations of the Controlled Substances Act or regulations. Proceeds through DEA administrative hearing.
• Immediate Suspension Orders. The federal equivalent of MBC Interim Suspension Orders. DEA can seek ISO where imminent public health risk is alleged.
• DEA registration surrender or revocation. Loss of DEA registration effectively ends controlled substance prescribing capability regardless of California license status.
• Parallel criminal investigation. Where DEA concludes that diversion was intentional, criminal investigation through the US Attorney’s Office may follow. Criminal exposure changes the defense calculus substantially.
• California Department of Justice Health Quality Investigation Unit. The state-level unit that handles criminal-adjacent MBC investigations, including prescribing cases with potential criminal elements.
• Information sharing. Both MBC and DEA share investigation information through established channels, and matters that begin in one forum often progress in parallel in the other.
• Distinct counsel requirements. DEA defense requires its own specialisation. MBC defense attorneys experienced in parallel DEA matters are the appropriate choice for California physicians facing both proceedings.

Documenting Informed Consent and Risk-Benefit Analysis

Informed consent documentation is the cornerstone of any credible defense in an opioid prescribing case. The California standard of care has evolved substantially over the past decade, and the Medical Board of California expectation is now specific written consent for opioid therapy rather than general surgical-style consent.

A robust informed consent framework for California physicians prescribing chronic opioids includes the following.

1. Specific written opioid consent document. Signed by the patient before long-term opioid therapy begins, covering the specific risks of opioid therapy including dependence, tolerance, overdose, and interaction with other substances.
2. Documented risk-benefit analysis. Entry in the medical record documenting the specific clinical reasoning for choosing opioid therapy, including the non-opioid alternatives considered and why they are not appropriate or have failed.
3. Controlled substance agreement. Separate signed agreement specifying patient obligations including single-prescriber arrangement, single-pharmacy arrangement, CURES participation, urine drug screening, appointment attendance, and prescription security.
4. CURES check at initiation. Documented CURES consultation at the start of therapy and periodically throughout, with findings recorded in the medical record.
5. Periodic functional assessment. Documented assessment of pain, function, mood, and quality of life at each visit, with objective measures where possible.
6. Documented review of CDC opioid prescribing guidelines. Reference to the CDC guideline on opioid prescribing for chronic pain, confirming that the prescribing is consistent with or explaining deviation from those guidelines.
7. Urine drug screen documentation. Periodic urine drug screening with documented results and response to aberrant findings.
8. Taper attempts. Documented periodic consideration of dose reduction or discontinuation, with reasoning for continuation at current dose.
9. Multimodal pain management documentation. Evidence of concurrent non-opioid interventions including physical therapy, psychological support, procedural interventions where appropriate, and lifestyle modifications.
10. Documented communication with other providers. Coordination with other treating clinicians including primary care, pain specialists, and mental health providers.

Remediation and Return to Prescribing After Medical Board of California Action

Where an MBC matter involves prescribing, the Decision or Stipulated Settlement commonly includes controlled substance prescribing restrictions. Understanding the pathway back to restored prescribing privileges is important for physicians in this situation.

The typical post-Decision prescribing restrictions and the return pathway include the following.

• Scope restrictions. The Decision may restrict prescribing to specific schedules (no Schedule II, for example), specific drug classes (no opioids), or specific patient populations (no chronic pain patients).
• Supervised prescribing. Requirement to prescribe controlled substances only under review by a Board-approved supervising physician who reviews the prescribing decisions.
• Enhanced documentation requirements. Specific documentation standards applying to all controlled substance prescribing, typically exceeding ordinary standards.
• Mandatory prescribing CME. Specific CME hours on prescribing, pain management, and substance use disorder treatment, often from specific accredited providers.
• Urine drug screening for prescribers. In cases involving potential impairment, the physician may be subject to testing during probation.
• Periodic CURES audits. The probation inspector conducts periodic reviews of the physician’s CURES activity.
• DEA coordination. Where DEA has also imposed restrictions, California prescribing may be subject to federal conditions as well.
• Return pathway. After successful completion of probationary restrictions, the physician may petition for modification or early termination of conditions. Full return to unrestricted prescribing requires sustained compliance and documented safe prescribing over the restricted period.

Preventing Prescribing Investigations Through Structured Practice Habits

The most reliable protection against an MBC opioid prescribing investigation is the structural practice habits that produce a prescribing profile consistent with current standards.

California physicians should build the following habits into routine practice regardless of whether any specific investigation is anticipated.

1. CURES consultation built into workflow. Every controlled substance prescription preceded by CURES consultation, documented in the medical record. Treated as non-negotiable rather than discretionary.
2. Standard consent package. Every chronic opioid patient signs a standard opioid consent document and controlled substance agreement at initiation, reviewed annually.
3. CDC guideline alignment. Prescribing practices documented as consistent with the CDC opioid prescribing guideline, with explicit reasoning for any deviation.
4. Dose discipline. MME calculations performed and documented for every chronic patient, with particular attention to the 50 and 90 MME thresholds.
5. No concurrent benzodiazepine and opioid prescribing. Except in carefully documented specific circumstances with clear clinical reasoning.
6. Regular urine drug screening. Periodic screening for chronic opioid patients with documented response to aberrant findings.
7. Periodic self-audit. Quarterly review of own prescribing patterns using CURES reports, identifying outlier patients for clinical review.
8. Continuous prescribing CPD. Substantial CPD on prescribing standards, pain management, and substance use disorder treatment, well above the California statutory minimum.
9. MATE Act compliance documentation. Current completion of the 8-hour MATE Act training documented and maintained.
10. Peer consultation on complex cases. Documented peer consultation for complex chronic pain cases, demonstrating ongoing accountability.

What California Doctors Say About Our Courses

Frequently Asked Questions

Official California Regulatory Resources

Every California physician prescribing controlled substances should be familiar with the following official California resources:

• Medical Board of California — The state licensing authority for all allopathic physicians in California, including all prescribing-related disciplinary proceedings. Visit www.mbc.ca.gov
• California Department of Justice — CURES 2.0 — California’s Prescription Drug Monitoring Program used by physicians and investigators to review controlled substance prescribing data. Visit oag.ca.gov/cures
• California Department of Consumer Affairs — BreEZe License Search — Public license lookup showing current license status and any public disciplinary history. Visit www.breeze.ca.gov